BC is a heterogeneous disease and is generally classified according to stage, hormone receptor (HR: estrogen receptor [ER] and/or progesterone receptor [PR]), and Human Epidermal Growth Factor Receptor 2 (HER2), which guide treatment decisions [2, 3]. This evidence concerns the gene NR4A1 and breast cancer.